Hair regrowth following a wnt- and follistatin-containing treatment: Safety and efficacy in a first-in-man phase 1 clinical trial

Journal of Drugs in Dermatology

Volumn 10, Issue 11, 2011, Pages 1308-1312

  Zimber, Michael P ^a   Ziering, Craig ^b   Zeigler, Fraink ^a   Hubka, Mark ^a   Mansbridge, Jonathan N ^a   Baumgartner, Mark ^a   Hubka, Kelsea ^a   Kellar, Robert ^a   Perez Meza, David ^c   Sadick, Neil ^d   Naughton, Gail K ^a  

^a Histogen Inc ^*  (United States)

^b Ziering Medical   (United States)

^c Permanent Hair Solutions Consulting   (United States)

^d Sadick Dermatology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGICAL AGENT; FOLLISTATIN; HAIR STIMULATING COMPLEX; PLACEBO; REPIFERMIN; UNCLASSIFIED DRUG; VASCULOTROPIN; WNT7A PROTEIN;

ADULT; ARTICLE; BIOENGINEERING; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HAIR GROWTH; HAMARTOMA; HISTOPATHOLOGY; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; IN VITRO STUDY; MALE; MALE TYPE ALOPECIA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SKIN BIOPSY; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; ALOPECIA; BIOENGINEERING; DOUBLE-BLIND METHOD; FIBROBLAST GROWTH FACTOR 7; FOLLISTATIN; HUMANS; INJECTIONS, INTRADERMAL; MALE; MIDDLE AGED; PILOT PROJECTS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WNT PROTEINS; YOUNG ADULT;

EID: 80655144826     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Kishimoto J, Burgeson RE, Morgan BA. Wnt signaling maintains the hair-inducing activity of the dermal papilla. Genes Dev. 2000;14:1181-1185. (Pubitemid 30327499)
2. Greco V, Chen T, Rendi M et al. A two-step mechanism for stem cell activation during hair regeneration. Cell Stem Cell. 2009;4:155-169.
3. Ito M, Yang Z, Andl T, et al. Wnt-dependent de novo hair follicle regeneration in adult mouse skin after wounding. Nature. 2007;47:316-320. (Pubitemid 46788832)
4. Nakamura M, Matzuk MM, Gerstmayer B, et al. Control of pelage hair follicle development and cycling by complex interactions between follistatin and activin. FASEB J. 2003;17:497-499.
5. Kashour T, Burton T, Dilbrov A, Amara F. Myogenic signaling by lithium in cardiomyoblasts is Akt independent but requires activation of the beta-catenin-Tcf/Lef pathway. J Mol Cell Cardiol. 2003;35:937-951. (Pubitemid 36871019)
6. Maurer M, Handjiski B, Paus R. Hair growth modulation by topical immunophilin ligands: Induction of anagen, inhibition of massive catagen development, and relative protection from chemotherapy-induced alopecia. Am J Pathol. 1997:150:1433-1441. (Pubitemid 27152660)
7. Plikus MV, Mayer JA, et al. Cyclic dermal BMP signalling regulates stem cell activation during hair regeneration. Nature. 2008;451:340-344.
8. Lowry WE, Blanpain C, Nowak JA, et al. Defining the impact of beta- catenin/Tcf transactivation on epithelial stem cells. Genes Dev. 2005;19:1596-1611. (Pubitemid 41003002)
9. Alonso L, Fuchs E. Stem cells in the skin: Waste not, Wnt not. Genes Dev. 2003;17:1189-1200. (Pubitemid 36583161)
10. Andl T, Reddy ST, Gaddapara T, Millar SE. WNT signals are required for the initiation of hair follicle development. Dev Cell. 2002;2:643-653.
11. Van Mater D, Kolligs FT, Dlugosz AA, Fearon ER. Transient activation of beta-catenin signaling in cutaneous keratinocytes is sufficient to trigger the active growth phase of the hair cycle in mice. Genes Dev. 2003;17:1219-1224. (Pubitemid 36583165)
12. Olsen EA, Weiner MS. Topical minoxidil in male pattern baldness: Effects of discontinuation of treatment. J Am Acad Dermatol. 1987;17:97-101. (Pubitemid 17087203)
13. Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol. 1999;41:717-721. (Pubitemid 29514026)
14. Tosti A, Iorizzo M, Vincenzi C. Finasteride treatment may not prevent telogen effluvium after minoxidil withdrawal. Arch Dermatol. 2003;139:1221-1222.
15. Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol. 2002;2:38-49.